These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31300979)

  • 1. Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
    Alten R; Feist E; Lorenz HM; Nüßlein H; Voll RE; Chartier M; Elbez Y; Rauch C
    Clin Rheumatol; 2019 Nov; 38(11):3049-3059. PubMed ID: 31300979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.
    Peichl P; Alten R; Galeazzi M; Lorenz HM; Nüßlein H; Navarro F; Elbez Y; Chartier M; Hackl R; Rauch C; Connolly SE
    Wien Med Wochenschr; 2020 Apr; 170(5-6):132-140. PubMed ID: 31654156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
    Alten R; Mariette X; Lorenz HM; Nüßlein H; Galeazzi M; Navarro F; Chartier M; Heitzmann J; Poncet C; Rauch C; Le Bars M
    Clin Rheumatol; 2019 May; 38(5):1413-1424. PubMed ID: 30790095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
    Alten R; Mariette X; Flipo RM; Caporali R; Buch MH; Patel Y; Marsal S; Sanmartí R; Nurmohamed MT; Griffiths H; Peichl P; Bannert B; Chartier M; Connolly SE; Lozenski K; Rauch C
    Clin Rheumatol; 2022 Aug; 41(8):2361-2373. PubMed ID: 35536413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study.
    Westhovens R; Connolly SE; Margaux J; Vanden Berghe M; Maertens M; Van den Berghe M; Elbez Y; Chartier M; Baeke F; Robert S; Malaise M
    Rheumatol Int; 2020 Sep; 40(9):1409-1421. PubMed ID: 32556473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
    Alten R; Mariette X; Lorenz HM; Galeazzi M; Cantagrel A; Nüßlein HG; Chartier M; Elbez Y; Rauch C; Le Bars M
    RMD Open; 2017; 3(2):e000538. PubMed ID: 29435360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
    Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML
    BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
    Alten R; Tony HP; Bannert B; Nüßlein H; Rauch C; Connolly SE; Chartier M; Lozenski K; Hackl R; Forster A; Peichl P
    Clin Rheumatol; 2023 Sep; 42(9):2321-2334. PubMed ID: 37314665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
    Mariette X; Alten R; Nüßlein HG; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
    Joint Bone Spine; 2017 Oct; 84(5):571-576. PubMed ID: 28043761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
    Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
    BMC Musculoskelet Disord; 2015 Jul; 16():176. PubMed ID: 26228643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
    Lee JS; Ahmad H; Shim SC; Bae SC; Song YW; Lee EY
    Patient; 2019 Jun; 12(3):319-326. PubMed ID: 30484084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year abatacept retention rate in clinical practice in the French ACTION cohort.
    Mariette X; Schaeverbeke T; Gaudin P; Chartier M; Heitzmann J; Vannier-Moreau V; Hilliquin P; Cantagrel A
    Joint Bone Spine; 2019 Nov; 86(6):753-759. PubMed ID: 31352138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis.
    Takahashi N; Kojima T; Kida D; Kaneko A; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Hanabayashi M; Kato T; Funahashi K; Hayashi M; Tsuboi S; Kanayama Y; Sobue Y; Asai N; Matsumoto T; Watanabe T; Asai S; Ishiguro N
    Clin Rheumatol; 2019 Sep; 38(9):2451-2459. PubMed ID: 31102087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study.
    Flipo RM; Constantin A; Goupille P; Chartier M; Ohayon A; Mariette X
    Clin Exp Rheumatol; 2024 Jul; 42(7):1377-1386. PubMed ID: 38436358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
    Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
    Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register.
    Cagnotto G; Willim M; Nilsson JÅ; Compagno M; Jacobsson LTH; Saevarsdottir S; Turesson C
    Arthritis Res Ther; 2020 Jan; 22(1):15. PubMed ID: 31969172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real-world setting in Taiwan.
    Chen KH; Li KJ; Fang YF; Hsieh SC; Chen YC; Lee CS; Luo SF; Cheng TT; Tsai WC; Lo YC; Lan JL
    Int J Rheum Dis; 2024 Jul; 27(7):e15199. PubMed ID: 39010815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
    Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Peichl P; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
    Clin Exp Rheumatol; 2016; 34(3):489-99. PubMed ID: 26966919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.